✦ LIBER ✦

Fatal outcome in a liver transplant recipient treated with activated protein C

✍ Scribed by Jana Hudcova; Roman Schumann

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 47 KB
Volume: 15
Category: Article
ISSN: 1527-6465
DOI: 10.1002/lt.21872

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Use of activated protein c in liver tran

Use of activated protein c in liver transplantation patients with septic shock

✍ Laura Rinaldi; Marco Marietta; Mariano Alejandro Mignini; Lara Donno; Stefano Bu 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB

Recombinant human activated protein C (rhAPC) has been approved for use in patients with severe sepsis at high risk of death. Because of the high risk of bleeding, liver transplantation (LT) patients have been excluded from the randomized control trials that evaluated efficacy and safety of rhAPC an

Anti-erythropoietin antibody–mediated pu

Anti-erythropoietin antibody–mediated pure red cell aplasia in a living donor liver transplant recipient treated for hepatitis C virus

✍ Jordan M. Schecter; J. Gregory Mears; Bachir Alobeid; Paul J. Gaglio 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 1 views

After liver transplantation, reinfection of the newly engrafted liver with hepatitis C virus is essentially universal in patients who are viremic at the time of transplantation. Treatment with interferon preparations with or without ribavirin is recommended in patients with marked histologic injury;

Early hepatic stellate cell activation i

Early hepatic stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis C

✍ Mark W. Russo; Roberto J. Firpi; David R. Nelson; Robert Schoonhoven; Roshan Shr 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 313 KB 👁 1 views

Recurrent hepatitis C after liver transplantation is a serious problem faced by liver transplant recipients. Activation of hepatic stellate cells is an early step in hepatic fibrogenesis. The aim of this study was to evaluate hepatic stellate cell activation, early after liver transplantation, as a

Heparin-induced thrombocytopenia and fat

Heparin-induced thrombocytopenia and fatal thrombosis in a patient with activated protein C resistance

✍ J. Gardyn; P. Sorkin; Y. Kluger; S. Kabili; J. M. Klausner; A. Zivelin; Prof A. 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 367 KB 👁 2 views

Genetic variability of hepatitis C virus

Genetic variability of hepatitis C virus NS3 protein in human leukocyte antigen-A2 liver transplant recipients with recurrent hepatitis C

✍ F. Xavier López-Labrador; Marina Berenguer; Amparo Sempere; Martín Prieto; Rafae 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 200 KB 👁 1 views

The association between the severity of chronic hepatitis C and the variability of the hepatitis C virus (HCV) genome remains controversial, but to our knowledge few data are available to date regarding T-cell epitope coding regions in transplant patients. In the current study, we identified 21 huma

Outcomes in liver transplant recipients

Outcomes in liver transplant recipients with hepatitis B virus: Resistance and recurrence patterns from a large transplant center over the last decade

✍ Guy W. Neff; Christopher B. O'Brien; Jose Nery; Norah Shire; Marzia Montalbano; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB

Hepatitis B virus (HBV) recurrence following liver transplantation (LTx) has been controllable primarily with the use of hepatitis B immune globulin (HBIg) and lamivudine (LAM). However, HBV resistance to LAM and/or HBIg has become an increasing problem prompting the use of newer antiviral agents. T